Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations
about
Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic reviewEfficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.Identifying good responders to glucose lowering therapy in type 2 diabetes: implications for stratified medicine.Exenatide's effect in reducing weight and glycosylated hemoglobin level in an Arab population with type 2 diabetesExenatide extended-release; clinical trials, patient preference, and economic considerations.Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years.Once weekly exenatide: efficacy, tolerability and place in therapy.Pathophysiological and pharmacological rationale for the use of exenatide once weekly in patients with type 2 diabetesEfficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis.Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program.Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.Real-world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project.Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
P2860
Q28076726-A04E4299-6099-4BEC-BA12-89C237850661Q30643065-58B5D674-FA2A-483F-B550-472405662436Q33626001-E59D4EEA-2325-4A2F-8F89-289E4FEBEEABQ33824522-5C288297-549A-4F11-B98B-54E0FEBAC6DBQ34395551-5785692E-AECD-4381-BDB8-76E462732E6DQ35183579-10F82DA3-EC88-4B4F-A164-3E3961B70A6BQ36538817-B559E8AD-1C24-42FA-A3E7-5D965F03C62DQ37384963-59D72166-6FA8-455C-85ED-6DD749CC3978Q38083112-BFEDC057-338A-42E9-8813-22EA00CD66E6Q38188871-878DBD9C-DA6A-42F5-98FC-FC0E38C65004Q38450276-D1A1CB5B-6F9B-4A67-87C3-25BB63963622Q38907259-759F76E1-B3EF-4652-9368-EDD0F169CEE9Q47588862-880834EF-AA13-4FED-9859-EE1CD29154D9Q48222857-5609CDBE-C51E-436A-A8CA-A63EF31A3980Q48228283-9A515935-2C34-4E65-94DF-8061E79471C8Q51246605-F0CAB621-20D9-493D-8D71-2376B04183D6Q55340049-CBE8974B-938D-4E2A-AA17-7ACB12985366
P2860
Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Exenatide once weekly for the ...... lity in patient subpopulations
@ast
Exenatide once weekly for the ...... lity in patient subpopulations
@en
type
label
Exenatide once weekly for the ...... lity in patient subpopulations
@ast
Exenatide once weekly for the ...... lity in patient subpopulations
@en
prefLabel
Exenatide once weekly for the ...... lity in patient subpopulations
@ast
Exenatide once weekly for the ...... lity in patient subpopulations
@en
P2093
P2860
P1476
Exenatide once weekly for the ...... lity in patient subpopulations
@en
P2093
P2860
P304
P356
10.1111/J.1742-1241.2012.03006.X
P577
2012-08-24T00:00:00Z